Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8795384 | 0.85 | PTGDR2 (0.42) | PTGDR2 | |
| SCHEMBL11005729 | 0.85 | HSPA1A (0.37) | PTGDR2PTGS2PTGS1 | |
| SCHEMBL27951692 | 0.77 | ADRA2A (0.47) | PTGDR2P2RX7 | |
| SCHEMBL27490447 | 0.75 | AR (0.32) | P2RX7AKR1B1 | |
| SCHEMBL1846189 | 0.73 | MAP3K14 (0.50) | PTGDR2 | |
| SCHEMBL5156684 | 0.72 | KDM4C (0.44) | PTGDR2 | |
| SCHEMBL11164856 | 0.71 | PTGDR2 (0.42) | PTGDR2AKR1B1 | |
| SCHEMBL27833962 | 0.71 | PTGDR2 (0.47) | PTGDR2 | |
| SCHEMBL8794695 | 0.71 | KDM4E (0.39) | P2RX7 | |
| SCHEMBL20480108 | 0.71 | ADRA2A (0.47) | PTGDR2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| EP-0011426-A1 | Halogen-substituted benzopyran- and benzothiopyran-4-carboxylic acids, their preparation and pharmaceutical compositions containing the same | PFIZER INC. (US) | 1980-05-28 | — | — | EP | claimed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| US-4210663-A | ALDOSE REDUCTASE INHIBITORS; TREATMENT OF DIABETIC CATARACTS, NEUROPATHY OR RETINOPATHY | PFIZER INC. (US) | 1980-07-01 | — | — | US | disclosed |
| US-4210663-A | ALDOSE REDUCTASE INHIBITORS; TREATMENT OF DIABETIC CATARACTS, NEUROPATHY OR RETINOPATHY | PFIZER INC. (US) | 1980-07-01 | — | — | US | disclosed |
| EP-0011426-A1 | Halogen-substituted benzopyran- and benzothiopyran-4-carboxylic acids, their preparation and pharmaceutical compositions containing the same | PFIZER INC. (US) | 1980-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | PTGDR2 759/4885P2RX7 232/4885AKR1B1 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.